NEOS Investment Management LLC Invests $436,000 in Corvus Pharmaceuticals, Inc. $CRVS

NEOS Investment Management LLC bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 59,202 shares of the company’s stock, valued at approximately $436,000. NEOS Investment Management LLC owned approximately 0.08% of Corvus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. GSA Capital Partners LLP increased its position in Corvus Pharmaceuticals by 25.9% in the 3rd quarter. GSA Capital Partners LLP now owns 401,407 shares of the company’s stock valued at $2,958,000 after acquiring an additional 82,675 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Corvus Pharmaceuticals by 5.8% during the third quarter. Vanguard Group Inc. now owns 3,471,925 shares of the company’s stock valued at $25,588,000 after purchasing an additional 191,216 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Corvus Pharmaceuticals by 6.0% in the third quarter. JPMorgan Chase & Co. now owns 32,232 shares of the company’s stock valued at $238,000 after purchasing an additional 1,812 shares in the last quarter. Rhumbline Advisers raised its position in Corvus Pharmaceuticals by 8.7% in the 3rd quarter. Rhumbline Advisers now owns 82,590 shares of the company’s stock worth $609,000 after purchasing an additional 6,640 shares during the last quarter. Finally, Shelton Wealth Management LLC acquired a new position in Corvus Pharmaceuticals during the 3rd quarter worth $101,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Trading Down 5.5%

Shares of CRVS opened at $16.57 on Friday. The stock has a market cap of $1.39 billion, a P/E ratio of -31.26 and a beta of 0.73. Corvus Pharmaceuticals, Inc. has a 1 year low of $2.54 and a 1 year high of $26.95. The stock’s 50-day moving average price is $13.64 and its two-hundred day moving average price is $9.30.

Analyst Ratings Changes

Several research firms have recently commented on CRVS. HC Wainwright lifted their target price on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Barclays lifted their price objective on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, January 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Thursday, December 11th. Finally, Jefferies Financial Group boosted their price target on shares of Corvus Pharmaceuticals from $13.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $31.80.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.